Becaplermin

From WikiProjectMed
Jump to navigation Jump to search
Becaplermin
Names
Trade namesRegranex
Clinical data
Drug classplatelet-derived growth factor.[1]
Main usesDiabetic foot ulcer due to neuropathy[1]
Side effectsRed rash[1]
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
use		Topical
External links
AHFS/Drugs.comMonograph
MedlinePlusa699049
Legal
Legal status

Becaplermin, sold under the brand name Regranex, is a medication used for diabetic foot ulcer of the leg due to neuropathy.[1] It is only used in cases that have sufficient blood supply.[1] It is applied to the skin.[1]

Common side effects include a red rash.[1] Other side effects may include cancer.[1] Safety in pregnancy is unclear.[2] It is a platelet-derived growth factor.[1]

Becaplermin was approved for medical use in the United States in 1997.[1] While it was approved for use in Europe in 1999, this approval was subsequently withdrawn.[3] It was refused approval for gum tissue loss in Europe in 2009.[4] In the United States it costs about 1,200 USD for a 15 gram tube as of 2022.[5]

Medical uses

The drug is used for the treatment of diabetic foot ulcers.[6] Studies of becaplermin showed that when used with good wound care, complete healing significantly increased and the ulcers healed on average 6 weeks faster.[7] Pharmacoeconomic studies reinforce the cost effectiveness of becaplermin as an adjunct to good wound care.[8]

The amount of becaplermin to be applied will vary depending upon the size of the ulcer area. Becaplermin should be stored in the refrigerator.[9] Analysis of healing human wounds showed that PDGF-BB induces fibroblast proliferation and differentiation and was found to increase healing in patients with decreased healing capacity, such as people living with diabetes. [10]

Contraindications

Becaplermin must not be used at the site of a skin cancer.[11]

Side effects

The most common side effects in clinical studies were erythematous rashes.[11]

A boxed warning has been added to the safety label to describe an increase rate of death from cancer when three or more tubes are used.[12] Regranex should be used with caution in patients with known malignancy.[9]

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 "DailyMed - REGRANEX- becaplermin gel". dailymed.nlm.nih.gov. Archived from the original on 24 March 2021. Retrieved 8 January 2022.
  2. ↑ "Becaplermin Monograph for Professionals". Drugs.com. Retrieved 8 January 2022.
  3. ↑ "Regranex". Archived from the original on 11 January 2022. Retrieved 8 January 2022.
  4. ↑ "Gemesis". Archived from the original on 5 April 2021. Retrieved 8 January 2022.
  5. ↑ "Becaplermin Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 8 January 2022.
  6. ↑ Nagai MK, Embil JM (February 2002). "Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers". Expert Opinion on Biological Therapy. 2 (2): 211–8. doi:10.1517/14712598.2.2.211. PMID 11849120. S2CID 28408255.
  7. ↑ Wieman TJ, Smiell JM, Su Y (May 1998). "Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study". Diabetes Care. 21 (5): 822–7. doi:10.2337/diacare.21.5.822. PMID 9589248. S2CID 20595962.
  8. ↑ Persson U, Willis M, Odegaard K, Apelqvist J (2000). "The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data". Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research. 3 Suppl 1: 39–46. doi:10.1046/j.1524-4733.2000.36027.x. PMID 16464208.
  9. ↑ 9.0 9.1 "REGRANEX Gel Highlights of Prescribing Information" (PDF). Smith & Nephew, Inc. Archived from the original (PDF) on 26 August 2016.
  10. ↑ Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 1999;79:1283-1316.
  11. ↑ 11.0 11.1 FDA Professional Drug Information for Regranex.
  12. ↑ Waknine Y (9 June 2008). "Diabetic Ulcer Gel Gets Black Box Warning". Medscape. Archived from the original on 24 June 2019. Retrieved 14 October 2021.

External links

Identifiers:
Retrieved from "https://mdwiki.org/w/index.php?title=Becaplermin&oldid=1384580"